1. Microbiology and Infectious Disease
  2. Neuroscience

The sheddase ADAM10 is a potent modulator of prion disease

  1. Hermann C Altmeppen
  2. Johannes Prox
  3. Susanne Krasemann
  4. Berta Puig
  5. Katharina Kruszewski
  6. Frank Dohler
  7. Christian Bernreuther
  8. Ana Hoxha
  9. Luise Linsenmeier
  10. Beata Sikorska
  11. Pawel P Liberski
  12. Udo Bartsch
  13. Paul Saftig
  14. Markus Glatzel  Is a corresponding author
  1. University Medical Center Hamburg-Eppendorf, Germany
  2. Christian Albrechts University, Germany
  3. Medical University Lodz, Poland
https://doi.org/10.7554/eLife.04260
Share this article
Cite this article
  1. Hermann C Altmeppen
  2. Johannes Prox
  3. Susanne Krasemann
  4. Berta Puig
  5. Katharina Kruszewski
  6. Frank Dohler
  7. Christian Bernreuther
  8. Ana Hoxha
  9. Luise Linsenmeier
  10. Beata Sikorska
  11. Pawel P Liberski
  12. Udo Bartsch
  13. Paul Saftig
  14. Markus Glatzel
(2015)
The sheddase ADAM10 is a potent modulator of prion disease
eLife 4:e04260.
https://doi.org/10.7554/eLife.04260
  2. Download BibTeX
  3. Download .RIS

Abstract

The prion protein (PrPC) is highly expressed in the nervous system and critically involved in prion diseases where it misfolds into pathogenic PrPSc. Moreover, it has been suggested as a receptor mediating neurotoxicity in common neurodegenerative proteinopathies such as Alzheimer's disease. PrPC is shed at the plasma membrane by the metalloprotease ADAM10 yet the impact of this on prion disease remains enigmatic. Employing conditional knockout mice, we show that depletion of ADAM10 in forebrain neurons leads to posttranslational increase of PrPC levels. Upon prion infection of these mice, clinical, biochemical, and morphological data reveal that lack of ADAM10 significantly reduces incubation times and increases PrPSc formation. In contrast, spatiotemporal analysis indicates that absence of shedding impairs spread of prion pathology. Our data support a dual role for ADAM10-mediated shedding and highlight the role of proteolytic processing in prion disease.

Article and author information

Author details

  1. Hermann C Altmeppen

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  2. Johannes Prox

    Institute of Biochemistry, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.

  3. Susanne Krasemann

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  4. Berta Puig

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  5. Katharina Kruszewski

    Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  6. Frank Dohler

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  7. Christian Bernreuther

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  8. Ana Hoxha

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  9. Luise Linsenmeier

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  10. Beata Sikorska

    Department of Molecular Pathology and Neuropathology, Medical University Lodz, Lodz, Poland
    Competing interests
    The authors declare that no competing interests exist.

  11. Pawel P Liberski

    Department of Molecular Pathology and Neuropathology, Medical University Lodz, Lodz, Poland
    Competing interests
    The authors declare that no competing interests exist.

  12. Udo Bartsch

    Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  13. Paul Saftig

    Institute of Biochemistry, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.

  14. Markus Glatzel

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    For correspondence
    m.glatzel@uke.de
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Bart De Strooper, VIB Center for the Biology of Disease, KU Leuven, Belgium

Ethics

Animal experimentation: Our study was carried out in accordance with the principles of laboratory animal care (NIH publication No. 86-23, revised 1985) as well as the recommendations in the Guide for the Care and Use of Laboratory Animals of the German Animal Welfare Act on protection of animals. The protocol was approved by the Committee on the Ethics of the Freie und Hansestadt Hamburg - Amt für Gesundheit und Verbraucherschutz (permit number 48/09, 81/07 and 84/13). Every effort was made to minimize suffering.

Version history

  1. Received: August 6, 2014
  2. Accepted: February 4, 2015
  3. Accepted Manuscript published: February 5, 2015 (version 1)
  4. Version of Record published: March 3, 2015 (version 2)

Copyright

© 2015, Altmeppen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,117
    views
  • 496
    downloads
  • 71
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hermann C Altmeppen
  2. Johannes Prox
  3. Susanne Krasemann
  4. Berta Puig
  5. Katharina Kruszewski
  6. Frank Dohler
  7. Christian Bernreuther
  8. Ana Hoxha
  9. Luise Linsenmeier
  10. Beata Sikorska
  11. Pawel P Liberski
  12. Udo Bartsch
  13. Paul Saftig
  14. Markus Glatzel
(2015)
The sheddase ADAM10 is a potent modulator of prion disease
eLife 4:e04260.
https://doi.org/10.7554/eLife.04260

Share this article

https://doi.org/10.7554/eLife.04260

Categories and tags

Research organism

Further reading

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics

    Modulation of biophysical properties of nucleocapsid protein in the mutant spectrum of SARS-CoV-2

    Ai Nguyen, Huaying Zhao ... Peter Schuck
    Research Article

    Genetic diversity is a hallmark of RNA viruses and the basis for their evolutionary success. Taking advantage of the uniquely large genomic database of SARS-CoV-2, we examine the impact of mutations across the spectrum of viable amino acid sequences on the biophysical phenotypes of the highly expressed and multifunctional nucleocapsid protein. We find variation in the physicochemical parameters of its extended intrinsically disordered regions (IDRs) sufficient to allow local plasticity, but also observe functional constraints that similarly occur in related coronaviruses. In biophysical experiments with several N-protein species carrying mutations associated with major variants, we find that point mutations in the IDRs can have nonlocal impact and modulate thermodynamic stability, secondary structure, protein oligomeric state, particle formation, and liquid-liquid phase separation. In the Omicron variant, distant mutations in different IDRs have compensatory effects in shifting a delicate balance of interactions controlling protein assembly properties, and include the creation of a new protein-protein interaction interface in the N-terminal IDR through the defining P13L mutation. A picture emerges where genetic diversity is accompanied by significant variation in biophysical characteristics of functional N-protein species, in particular in the IDRs.

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics

    Viral Variants: How mutations affect function

    Thomas Kuhlman
    Insight

    A new study reveals how naturally occurring mutations affect the biophysical properties of nucleocapsid proteins in SARS-CoV-2.

    1. Microbiology and Infectious Disease

    RNA polymerase III is involved in regulating Plasmodium falciparum virulence

    Gretchen Diffendall, Aurelie Claes ... Artur Scherf
    Research Article

    While often undetected and untreated, persistent seasonal asymptomatic malaria infections remain a global public health problem. Despite the presence of parasites in the peripheral blood, no symptoms develop. Disease severity is correlated with the levels of infected red blood cells (iRBCs) adhering within blood vessels. Changes in iRBC adhesion capacity have been linked to seasonal asymptomatic malaria infections, however how this is occurring is still unknown. Here, we present evidence that RNA polymerase III (RNA Pol III) transcription in Plasmodium falciparum is downregulated in field isolates obtained from asymptomatic individuals during the dry season. Through experiments with in vitro cultured parasites, we have uncovered an RNA Pol III-dependent mechanism that controls pathogen proliferation and expression of a major virulence factor in response to external stimuli. Our findings establish a connection between P. falciparum cytoadhesion and a non-coding RNA family transcribed by Pol III. Additionally, we have identified P. falciparum Maf1 as a pivotal regulator of Pol III transcription, both for maintaining cellular homeostasis and for responding adaptively to external signals. These results introduce a novel perspective that contributes to our understanding of P. falciparum virulence. Furthermore, they establish a connection between this regulatory process and the occurrence of seasonal asymptomatic malaria infections.